Management of Patients with Positive Chlamydia and Negative Gonorrhea Tests

Epidemiology of Coinfection

In patients with confirmed gonorrhea, concurrent chlamydia infection occurs in 20 %–42 % of cases, according to historic CDC surveillance data (MMWR 1993) 1.

The CDC warns that unnecessary gonorrhea treatment accelerates antimicrobial resistance, especially given the limited remaining therapeutic options for Neisseria gonorrhoeae (MMWR 2012) 3.
CDC treatment guidelines for confirmed gonorrhea recommend ceftriaxone 250 mg IM plus azithromycin 1 g orally to preserve susceptibility; this regimen should be reserved for proven infection (MMWR 2012) 3.

Treat chlamydia alone with either azithromycin 1 g orally as a single dose or doxycycline 100 mg orally twice daily for 7 days (CDC STI treatment guidelines, MMWR 2006 & 2010) [5][6].
Do not add gonorrhea therapy unless there is strong clinical suspicion despite a negative NAAT (Ann Intern Med 2002) 7.
Partner notification and treatment should focus on chlamydia exposure; partners do not require empiric gonorrhea therapy (CDC partner management recommendations, MMWR 2006) 5.

High‑risk epidemiologic factors (e.g., recent sexual contact with a known gonorrhea case or travel to regions with high gonorrhea prevalence) justify empiric dual therapy (MMWR 2002; Ann Intern Med 2002) [8][7].
Clinical signs suggestive of gonorrhea—such as purulent urethral or cervical discharge or severe dysuria—warrant empiric treatment (MMWR 2006) 5.
Uncertain follow‑up (patient unlikely to return for re‑testing) may merit empiric dual therapy to avoid missed infection (MMWR 2006 & 2010) [5][6].
Symptomatic mucopurulent cervicitis in settings where gonorrhea prevalence exceeds 15 % should be managed with empiric gonorrhea coverage (MMWR 1998) 9.

Specimen collection must include all relevant anatomic sites (genital, pharyngeal, rectal) for at‑risk populations to avoid missed gonorrhea infections (MMWR 2010) 6.
If testing occurs during the window period after exposure, a repeat NAAT in ≈2 weeks is recommended rather than immediate empiric therapy (MMWR 2006) 5.

Partners of patients with a confirmed chlamydia infection should be evaluated and treated for chlamydia only; automatic dual therapy for gonorrhea is not indicated (CDC partner management guidance, MMWR 2006) 5.